A Phase 2 interventional study of ARD-101 in Prader-Willi Syndrome, sponsored by Aardvark Therapeutics, Inc.. Completed at 2 sites in United States. Open to participants aged 17 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Aardvark Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Prader-Willi Syndrome with a site in United States — 9 open to participants now, 14 under way, 3 of them phase 3. Prader-Willi Syndrome · United States.
Among the 69 studies in Prader-Willi Syndrome with a site in United States, this one is the 32nd largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2022, is one of 17 in phase 2, and was the 45th registered.
144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.
Browse Prader-Willi Syndrome studies →9 of the 69 studies in Prader-Willi Syndrome with a site in United States are open now. Recruiting first, the newest first:
Children's Mercy Hospital Kansas City · Sites in United States
Ages 13–17
ConSynance Therapeutics · Sites in United States
Ages 13–50
Grace Kim · Sites in United States
Ages 18–26
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+ · Healthy volunteers
Harmony Biosciences Management, Inc. · Sites in United States, Australia, Belgium and 10 more countries
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.
This study: 17 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 23 · Phase 3 16 · Phase 4 3
First in 1999; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 30 across 100 interventional studies indexed under Prader-Willi Syndrome.
Median enrollment 23 across the 58 interventional studies, 200 across the 11 observational. Of the 51 that completed or were terminated, 21 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 69 have an industry lead sponsor. The 10 most frequent:
Aardvark Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.
Aardvark Therapeutics, Inc. has 3 studies filed under Prader-Willi Syndrome — fewer than ten, so there is no comparison to draw.
7 of the studies in Prader-Willi Syndrome with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06366464Phase 3Harmony Biosciences Management, Inc.A Study of Pitolisant in Patients With Prader-Willi Syndrome | 2027-04 |
| NCT06144645Phase 3Foundation for Prader-Willi ResearchA Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS | 2027-04-01 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06239116Rhythm Pharmaceuticals, Inc.A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment | 2027-05-07 |
| NCT07348601ConSynance TherapeuticsA Study of CSTI-500 in Patients With Prader-Willi Syndrome | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 69 studies in Prader-Willi Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ARD-101 in Patients with Prader-Willi Syndrome
This is a Phase 2, open-label study to investigate the effects of ARD-101 in subjects with Prader-Willi Syndrome. The study will consist of a Screening Period (up to 28 days), a Treatment Period (28 days), and a Follow-up Period (End-of-Study Visit within 14 days after receiving the last dose of ARD-101). The screening procedures will be initiated upon completion of the informed consent process. Following completion of screening procedures and confirmation of eligibility, subjects will be enrolled to receive ARD-101 in an outpatient setting and will be instructed to visit the clinical center periodically for safety and efficacy assessments.
ARD-101 will be provided as a fixed dose of 200 mg BID for 28 days (Group 1) and then in a dose escalation of 1 week at 400 mg BID, 1 week at 600 mg BID, then 2 weeks at 800 mg BID (Group 2).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ARD-101: 4 weeks dosing at 200 mg BID (twice daily)
Drug: ARD-101
ARD-101: 1 week at 400 mg BID (twice daily), second week at 600 mg BID, third and fourth weeks at 800 mg BID. Oral administration.
Drug: ARD-101
Oral administration of ARD-101 taken BID (twice daily) for 28 days.
Incidence of Treatment Emergent Adverse Events (TEAE)
The incidence of treatment emergent adverse events (TEAE) reported through the 28 days of treatment and the 14 days post treatment phase. TEAEs were those events occurring after treatment began.
Time frame: Adverse Events were collected from time of informed consent through end of study; approximately 70 days (28 days of screening, 28 days of treatment, 14 days post treatment follow up).
Efficacy Evaluation of Hyperphagia in Prader-Willi Syndrome
Quantitative evaluation of hyperphagia via the Hyperphagia Questionnaire for Clinical Trials (HQ-CT). The HQCT is a 9-item hyperphasia questionnaire which is validated for use in PWS clinical trials. Score will range from 0 (no hyperphagia behaviors) to 36 (most severe hyperphagia behaviors)
Time frame: Baseline, Day 15, Day 28
Change in Body Weight
Total weight change at the end of treatment (day 28) from baseline
Time frame: Baseline to day 28
| Milestone | Group 1 (Fixed Dose) | Group 2 (Dose Escalation) |
|---|---|---|
| Started | 13 | 6 |
| Completed | 12 | 6 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
Quantitative evaluation of hyperphagia via the Hyperphagia Questionnaire for Clinical Trials (HQ-CT). The HQCT is a 9-item hyperphasia questionnaire which is validated for use in PWS clinical trials. Score will range from 0 (no hyperphagia behaviors) to 36 (most severe hyperphagia behaviors)
| score on a scale | Group 1 (Fixed Dose) | Group 2 (Dose Escalation) |
|---|---|---|
| Baseline | 18 ± 4.41 | 20.2 ± 4.88 |
| Change from Baseline to Day 15 | -9.2 ± 4.26 | -5.0 ± 6.51 |
| Change from Baseline to Day 28 | -9.0 ± 4.80 | -4.0 ± 8.74 |
The incidence of treatment emergent adverse events (TEAE) reported through the 28 days of treatment and the 14 days post treatment phase. TEAEs were those events occurring after treatment began.
| Participants | ARD-101 (Fixed Dose) | ARD-101 (Dose Escalation) |
|---|---|---|
| Incidence of Treatment Emergent Adverse Events (TEAE) | 8 | 5 |
Total weight change at the end of treatment (day 28) from baseline
| kg | Group 1 (Fixed Dose) | Group 2 (Dose Escalation) |
|---|---|---|
| Change in Body Weight | 0.23 ± 1.556 | 1.02 ± 1.698 |
Collected over Adverse events (AEs) were collected and recorded for each patient from the date the ICF was signed until the end of follow up, up to 70 days. A treatment emergent adverse event (TEAE) is defined as an adverse event that occurs or worsens during a defined treatment period, up to 42 days (i.e., 28 days of treatment plus 14 days of follow up).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1 (Fixed Dose) | 0/13 (0%) | 0/13 (0%) | 8/13 (61.5%) |
| Group 2 (Dose Escalation) | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Event | Group 1 (Fixed Dose) | Group 2 (Dose Escalation) |
|---|---|---|
| HeadacheNervous system disorders | 3/13 | 3/6 |
| DysgeusiaNervous system disorders | 1/13 | 2/6 |
| IrritabilityPsychiatric disorders | 0/13 | 2/6 |
| DiarrheaGastrointestinal disorders | 2/13 | 1/6 |
| NauseaGastrointestinal disorders | 1/13 | 1/6 |
| AgitationPsychiatric disorders | 0/13 | 1/6 |
| Upper Respiratory Tract InfectionInfections and infestations | 0/13 | 1/6 |
| Gait DisturbanceGeneral disorders | 0/13 | 1/6 |
| TremorNervous system disorders | 1/13 | 0/6 |
| Abdominal PainGastrointestinal disorders | 1/13 | 0/6 |
| Age, Categorical(Participants) | Group 1 (Fixed Dose) | Group 2 (Dose Escalation) | Total |
|---|---|---|---|
| <=18 years | 1 | 1 | 2 |
| Between 18 and 65 years | 12 | 5 | 17 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Group 1 (Fixed Dose) | Group 2 (Dose Escalation) | Total |
|---|---|---|---|
| Mean | 23.8 ± 7.81 | 21.2 ± 3.54 | 22.9 ± 6.76 |
| Sex: Female, Male(Participants) | Group 1 (Fixed Dose) | Group 2 (Dose Escalation) | Total |
|---|---|---|---|
| Female | 9 | 3 | 12 |
| Male | 4 | 3 | 7 |
| Ethnicity (NIH/OMB)(Participants) | Group 1 (Fixed Dose) | Group 2 (Dose Escalation) | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 12 | 6 | 18 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group 1 (Fixed Dose) | Group 2 (Dose Escalation) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 0 | 1 | 1 |
| White | 11 | 5 | 16 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Group 1 (Fixed Dose) | Group 2 (Dose Escalation) | Total |
|---|---|---|---|
| United States | 13 | 6 | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2022 to primary completion in Sep 2024, 27 months.
Results were first posted in Sep 2026, 1 year 11 months after primary completion.
Of 11 phase 2 interventional studies under Prader-Willi Syndrome, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 27. This study's 27 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denatonium acetate monohydrate
Aardvark Therapeutics, Inc.